Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

This is a multi-institutional Phase I/II study of an allogeneic KIR-HLA mismatched NK cell infusion (AdaptNK) and a short course of subcutaneous interleukin-2 (IL-2) administered after lymphodepleting chemotherapy \[cyclophosphamide (CY)/fludarabine (FLU)\] in patients with relapsed or refractory acute myelogenous leukemia (AML). AdaptNK is a natural killer (NK) cell product that is enriched for NK cells with an "adaptive", or human cytomegalovirus (CMV)-induced, phenotype.

Trial Details

NCT ID
NCT07591649
Phase
PHASE1 / PHASE2
Sponsor
Masonic Cancer Center, University of Minnesota
Status
RECRUITING
Cancer Type
Leukemia
Interventions
  • AdaptNK
  • Fludarabine
  • Cyclophosphamide
  • IL-2
Locations (sample)
  • Minneapolis, Minnesota, United States|44.97997,-93.26384

Key Eligibility Criteria

  • 18-74 years with Karnofsky score ≥ 70%
  • 75 years and older: KPS ≥ 70%, HCT-CI \< 5 (excluding history of solid tumor), AND not frail by Fried frailty criteria (see Appendix III)
  • HLA type C1/C1 or C2/C2
  • Note: For easy determination, the definition of HLA-C ligand group assigments is included below:

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Leukemia Trials on Trialify →